Prolonged Response to Afatinib and Crizotinib in a Rare Case of
Humans
Crizotinib
/ therapeutic use
Female
Afatinib
/ therapeutic use
Aged
Proto-Oncogene Mas
Receptor, ErbB-2
/ genetics
ErbB Receptors
/ genetics
Lung Neoplasms
/ drug therapy
Proto-Oncogene Proteins
/ genetics
Protein-Tyrosine Kinases
/ genetics
Adenocarcinoma of Lung
/ drug therapy
Proto-Oncogene Proteins c-met
/ genetics
Mutation
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
EGFR-mutated NSCLC
NSCLC
drug combinations
molecular pathology
targeted therapies
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
30
03
2024
revised:
13
05
2024
accepted:
18
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
epublish
Résumé
We present the case of a 70-year-old never-smoking female patient with
Identifiants
pubmed: 38891886
pii: ijms25115698
doi: 10.3390/ijms25115698
pii:
doi:
Substances chimiques
Crizotinib
53AH36668S
ROS1 protein, human
EC 2.7.10.1
Afatinib
41UD74L59M
Proto-Oncogene Mas
0
Receptor, ErbB-2
EC 2.7.10.1
MAS1 protein, human
0
ErbB Receptors
EC 2.7.10.1
Proto-Oncogene Proteins
0
Protein-Tyrosine Kinases
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-met
EC 2.7.10.1
MET protein, human
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM